COMMUNIQUÉS West-GlobeNewswire

Corza Medical nommée « Meilleure société à l’échelle mondiale dans le domaine des technologies médicales » lors de la 8e édition du programme annuel des MedTech Breakthrough Awards

10/05/2024 - 02:08

Le prestigieux programme international de remise de prix organisé chaque année récompense les produits et entreprises qui se sont démarqués sur le plan de la santé numérique et des technologies médicales WESTWOOD, Mass [...]

Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results

10/05/2024 - 00:56

WEST LAFAYETTE, Ind., May 09, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development [...]

Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices

10/05/2024 - 00:30

PLEASANTON, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that four independent scientific abstracts accepted for the [...]

TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss First Quarter 2024 Financial Results on May 15, 2024

10/05/2024 - 00:10

FREDERICK, Md., May 09, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

09/05/2024 - 23:46

30 month median overall survival (OS); median OS independent of patient CPS score ORR 34% (CPS≥1); 48% (CPS≥20) Phase 3 registrational trial planned to initiate in 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- [...]

VitalHub Corp. Reports First Quarter 2024 Financial Results

09/05/2024 - 23:32

ARR up 21% YoY to $47.8 million Total Revenue up 21% to $15.3 million EBITDA up 56% YoY to $3.1 million TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) [...]

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

09/05/2024 - 23:00

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients [...]

Nova Leap Health Corp. Posts Q1 2024 Results

09/05/2024 - 23:00

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 09, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]

Quipt Home Medical Corp. Announces Filing of Final Base Shelf Prospectus

09/05/2024 - 23:00

CINCINNATI, Ohio, May 09, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, has filed [...]

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

09/05/2024 - 22:51

HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of [...]

23andMe to Report Q4 and Full Year FY2024 Financial Results

09/05/2024 - 22:50

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and [...]

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

09/05/2024 - 22:42

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society [...]

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

09/05/2024 - 22:30

Presentations highlight data supporting FILSPARI ® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- [...]

Theratechnologies Reports on its Annual Meeting of Shareholders

09/05/2024 - 22:30

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of [...]

Theratechnologies rend compte de son assemblée annuelle des actionnaires

09/05/2024 - 22:30

MONTRÉAL, 09 mai 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur le développement et la commercialisation de [...]

BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024

09/05/2024 - 22:30

MISSISSAUGA, Ontario, May 09, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2024 on Thursday, May 16, [...]

DBV Technologies to Participate in Upcoming Investor Conferences

09/05/2024 - 22:30

Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical [...]

Participation de DBV Technologies aux conférences investisseurs en mai

09/05/2024 - 22:30

Montrouge, France, le 9 mai Participation de DBV Technologies aux conférences investisseurs en mai DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT), une société biopharmaceutique au [...]

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

09/05/2024 - 22:29

Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAP Reported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual Meeting Published positive data from [...]